Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT | Synapse
August 1, 2024Open Access
Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
Key Points
Key points are not available for this paper at this time.
Abstract
Correlation between MGMT mRNA and MGTM protein abundance values in glioblastoma from the CPTAC database.